Multiple myeloma (MM) patients are at higher risk for severe COVID-19. Their mRNA vaccination response against SARS-CoV-2 is unknown. Thus, we analyzed responses to mRNA vaccination against COVID-19 among these patients…
Go to article Click Here
IMBCR & Emory University’s Big Discovery!!!
About Michael cacciotti
View all posts by Michael cacciottiSubscribe
Subscribe to our e-mail newsletter to receive updates.
James R. Berenson, MD
- President & CEO, Institute for Myeloma & Bone Cancer Research (IMBCR)
- President & Medical Director. Berenson Cancer Center (Berensoncancercenter)
- Founder & President, ONCOtherapeutics
- Founder & Principal, ONCOtracker
-
Cancer Patients Join Oncologist Who Releases Results of COVID-19 Vaccine/Cancer Study
-
IMBCR & Emory University’s Big Discovery!!!
-
James R. Berenson, MD, Inc. Announces Rebranding and Changes Organization Name to Berenson Cancer Center
- What Is Multiple Myeloma?
-
Video Updates
- Kyphon® Balloon Kyphoplasty Found Beneficial for Treating Spinal Fractures in Cancer Patients
- The histone deacetylase inhibitor LBH589 enhances the anti-myeloma effects of chemotherapy in vitro and in vivo
- Oncology CRO Oncotherapeutics Presents at ASH 2011 Annual Meeting
- Understanding Myeloma News About Secondary Cancers and Clotting
-
Dedication of “Determination”
February 7, 2022
Press Releases